Latest Intellectual Property News

Microba Life Sciences reported a robust Q2 FY25 with revenue more than doubling year-on-year, driven by strong sales of its MetaXplore microbiome test in Australia and promising early adoption in the UK.

Universal Biosensors is expanding its handheld testing portfolio with the upcoming AQUASCOUT water sensor and growing sales of its FDA-approved Xprecia Prime blood coagulation device, targeting multi-billion-dollar markets.

Anatara Lifesciences has been granted a key Australian patent for its GaRP gastrointestinal health product, reinforcing its intellectual property portfolio ahead of pivotal clinical trial results expected in March 2025.

PARKD Ltd reports substantial structural completions on flagship projects and positive operating cash flow in Q2 FY25, setting the stage for licensing negotiations with Fielders.

Zeotech Limited has secured a strategic MOU with Holcim Australia to advance its AusPozz™ low-carbon concrete product, alongside promising methane reduction results and a newly granted Japanese patent.

IperionX has completed its inaugural end-to-end titanium powder production cycle using its proprietary HAMR process and secured exclusive rights to breakthrough titanium technologies, positioning itself for expanded manufacturing capacity and strong market demand.

BrainChip Holdings reports a US$20 million cash balance and key defense contracts in its December 2024 quarterly update, underscoring its growing foothold in neuromorphic AI commercialization.

Vection Technologies has reported a milestone positive net cash flow in its traditionally weak quarter, driven by a 60% half-on-half revenue surge and strategic acquisition integration.

First Graphene has secured key patents for its Kainos Technology in Australia and Korea, positioning itself at the forefront of producing graphite, graphene, and hydrogen from petroleum waste. This milestone aligns with growing global demand for critical minerals essential to the energy transition.

InhaleRx has corrected its quarterly report and revealed a $38.5 million funding deal to fast-track clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, aiming for FDA approval.

K-TIG Limited is set to transform its business with a $7–10 million capital raise to acquire US-based Metal Powder Works, issuing performance-based vendor shares that an independent expert deems fair and reasonable.

Bod Science Limited reports a modest net cash inflow of $51,000 for Q2 FY2025, supported by increased customer receipts and intellectual property sales, while navigating a complex Deed of Company Arrangement and pending acquisition.